As with other anti-HIV medicines, patients taking Trizivir may be at risk of developing lipodystrophy (changes in the distribution of body fat), immune reactivation syndrome (reactions to disease-causing organisms by the recovering immune system) and osteonecrosis (death of cells in the bone, which makes the bones fragile).